AC100 Antibody

What is AC100 Antibody and what is its target protein?

AC100 Antibody is a polyclonal antibody that targets Actin-100 (AC100), a protein originally isolated from Solanum tuberosum (potato). The antibody recognizes epitopes on the AC100 protein, which is a fragment of the actin cytoskeletal protein . According to available data, commercial versions are typically produced in rabbit hosts and are available in various formulations for research applications .

How is AC100 Antibody produced and what formats are available?

AC100 Antibody is primarily available as a rabbit polyclonal antibody produced through immunization with recombinant Solanum tuberosum AC100 protein . The antibody is typically supplied in liquid form containing preservatives such as 0.03% Proclin 300 and stabilizers including 50% glycerol in phosphate-buffered saline (PBS) at pH 7.4. While polyclonal formats are most common, efforts in antibody technology are moving toward recombinant versions for improved reproducibility, as seen with other research antibodies .

What are the primary research applications for AC100 Antibody?

Based on supplier specifications, AC100 Antibody has been validated for the following applications:

• Western blotting (WB): Typically used at dilutions of 1:1,000

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection

• Immunofluorescence: For cellular localization studies

The antibody has been used in cell biology research to study cytoskeletal components and protein localization, particularly in plant systems and comparative studies .

What are the recommended protocols for using AC100 Antibody in Western blot applications?

For optimal Western blot results with AC100 Antibody:

• Sample preparation:

  • Lyse samples in buffer containing protease inhibitors

  • Denature proteins completely in loading buffer containing SDS and DTT/β-mercaptoethanol

  • Heat samples at 95°C for 5 minutes

• Electrophoresis and transfer:

  • Use 10-12% acrylamide gels for optimal resolution

  • Perform wet transfer at 100V for 60-90 minutes or 30V overnight

• Blocking and antibody incubation:

  • Block membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Dilute AC100 Antibody 1:1,000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3-4 times with TBST (10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody (anti-rabbit IgG)

  • Develop using enhanced chemiluminescence (ECL) detection

This protocol follows standard practices for polyclonal antibodies as evidenced in the literature on antibody validation practices .

How should the AC100 Antibody be validated before use in critical experiments?

Based on current best practices in antibody validation , researchers should:

• Validate specificity using multiple techniques:

  • Western blot: Confirm single band of expected molecular weight

  • Immunoprecipitation: Verify pull-down of target protein

  • Immunofluorescence: Check expected subcellular localization

• Employ negative controls:

  • Use knockout/knockdown samples when available

  • Include secondary antibody-only controls

  • Test pre-immune serum or isotype controls

• Perform independent validation not relying solely on manufacturer's data:

  • Test antibody performance in your specific experimental system

  • Compare with other antibodies targeting the same protein

  • Consider third-party validation services

The comprehensive third-party testing approach described by Ayoubi et al. (2023) provides an excellent model for antibody validation, showing that only about one-third of commercially available antibodies perform as expected across multiple applications .

How does AC100 Antibody compare to recombinant antibody technologies in terms of reproducibility and specificity?

Recent studies show significant advantages of recombinant antibodies over traditional polyclonal antibodies like AC100:

• Reproducibility comparison:

  • Polyclonal antibodies like AC100 show batch-to-batch variability due to their production in animals

  • Recombinant antibodies demonstrated superior performance in a comprehensive study of 614 commercial antibodies, with only about one-third of polyclonal antibodies recognizing their targets correctly

  • Sequence-defined recombinant antibodies ensure consistent production, eliminating variability issues

• Specificity analysis:

  • AC100 as a polyclonal preparation recognizes multiple epitopes, which can be advantageous for detection but may increase cross-reactivity

  • Recombinant antibodies can be engineered for enhanced specificity to single epitopes

  • The defined nature of recombinant antibodies allows for sequence-based optimization of specificity profiles

• Research implications:

  • Critical research requiring high reproducibility may benefit from recombinant alternatives

  • For established protocols using AC100, careful validation remains essential

  • Consider parallel testing with both antibody types for critical experiments

What are the potential cross-reactivity issues with AC100 Antibody and how can they be addressed?

Cross-reactivity is a significant concern with antibodies including AC100:

• Known cross-reactivity patterns:

  • As a polyclonal antibody, AC100 may recognize epitopes on structurally similar proteins

  • Actins are highly conserved across species, increasing potential cross-reactivity

  • The antibody may recognize multiple actin isoforms beyond the target AC100

• Experimental strategies to address cross-reactivity:

  • Absorption controls: Pre-incubate antibody with recombinant target protein to confirm specificity

  • Multiple antibody approach: Compare results with antibodies targeting different epitopes

  • Western blot analysis: Confirm single band of expected molecular weight

  • Mass spectrometry validation: Identify proteins recognized by the antibody through immunoprecipitation followed by MS analysis

• Interpretation guidelines:

  • Always include appropriate negative controls

  • Be cautious interpreting data from complex samples with multiple actin isoforms

  • Document all validation steps performed when publishing results

Studies like those by Andersson et al. (2017) highlight that the best-performing antibody is not always the most widely used, emphasizing the importance of proper validation .

How can AC100 Antibody be used in combination with other detection methods for comprehensive protein analysis?

Integrating multiple detection approaches enhances research rigor:

• Complementary methodologies:

  • Immunoblotting + Mass Spectrometry: Confirm antibody specificity through protein identification

  • Immunofluorescence + Proximity Ligation Assay: Validate protein interactions in situ

  • Immunoprecipitation + RNA-seq: Identify RNA-protein interactions

  • Flow Cytometry + Western Blot: Quantify protein expression across cell populations

• Implementation strategy:

  • Begin with established AC100 antibody protocols

  • Validate findings using orthogonal methods

  • Develop integrated workflows that maximize strengths of each approach

  • Document concordance and discordance between methods

• Data integration framework:

  • Create consolidated datasets that compare quantitative outputs across methods

  • Establish statistical approaches for reconciling methodological differences

  • Develop visualization tools that represent multi-method validation

This multi-method approach aligns with growing requirements for rigorous antibody-based research and addresses reproducibility concerns .

What are common issues encountered with AC100 Antibody in Western blotting and how can they be resolved?

Researchers frequently encounter these challenges:

• High background signal:

  • Cause: Insufficient blocking, excessive antibody concentration, or cross-reactivity

  • Solution: Optimize blocking (try 5% BSA instead of milk), increase washing time/frequency, further dilute antibody, use more stringent washing buffer

• Weak or no signal:

  • Cause: Insufficient protein, degraded antibody, inefficient transfer

  • Solution: Increase protein loading, verify antibody activity with positive control, optimize transfer conditions, extend exposure time

• Multiple bands or unexpected band size:

  • Cause: Cross-reactivity, protein degradation, post-translational modifications

  • Solution: Use fresh samples with protease inhibitors, compare with recombinant protein standard, perform peptide competition assay

• Inconsistent results between experiments:

  • Cause: Batch-to-batch antibody variability, inconsistent sample preparation

  • Solution: Use single antibody lot for entire study, standardize lysate preparation, include positive controls in each experiment

These troubleshooting approaches are based on established protocols and antibody validation literature .

How should AC100 Antibody be stored and handled to maintain optimal performance?

Proper storage and handling are critical for antibody performance:

• Storage conditions:

  • Store at -20°C for long-term preservation

  • Aliquot upon first thaw to prevent repeated freeze-thaw cycles

  • Add glycerol (final concentration 50%) for cryoprotection

  • Store working dilutions at 4°C for up to 2 weeks

• Handling best practices:

  • Avoid repeated freeze-thaw cycles (limit to <5)

  • Centrifuge vial briefly before opening

  • Use sterile techniques when handling antibody solutions

  • Allow cold antibody to equilibrate to room temperature before opening to prevent condensation

• Quality control monitoring:

  • Test antibody performance periodically with positive control samples

  • Document lot numbers and performance characteristics

  • Consider including internal standards in each experiment to track antibody performance over time

Following these guidelines maximizes antibody shelf-life and experimental consistency, addressing concerns about reproducibility in antibody-based research .

How can AC100 Antibody be applied in advanced imaging techniques?

Cutting-edge applications of AC100 Antibody in imaging include:

• Super-resolution microscopy applications:

  • STORM/PALM imaging requires careful antibody validation

  • Optimize antibody concentration (typically lower than conventional IF)

  • Consider direct labeling with photo-switchable fluorophores

  • Validate specificity with appropriate controls

• Live-cell imaging considerations:

  • Fragment antibody to improve cell penetration

  • Consider conjugation to cell-permeable peptides

  • Validate that antibody binding doesn't disrupt normal protein function

  • Establish optimal antibody:fluorophore ratio

• Multi-color imaging protocols:

  • Verify absence of spectral overlap between fluorophores

  • Establish sequential staining protocols to minimize cross-reactivity

  • Include appropriate controls for each fluorophore

These advanced applications require rigorous validation to ensure specific labeling and should follow general principles established for immunofluorescence applications .

What emerging technologies might replace traditional antibody-based detection methods like AC100 Antibody?

The field is evolving rapidly with alternatives to traditional antibodies:

• Alternative affinity reagents:

  • Aptamers: DNA/RNA-based binding molecules with high specificity

  • Affimers/Adhirons: Small non-antibody scaffold proteins

  • DARPins: Designed ankyrin repeat proteins with high stability

  • Nanobodies: Single-domain antibody fragments with improved tissue penetration

• CRISPR-based detection systems:

  • CRISPR-Cas13a systems for RNA detection

  • CRISPR-based tagging of endogenous proteins

  • Advantages include direct genomic integration and reduced reliance on antibody specificity

• Mass spectrometry advances:

  • Targeted proteomics using SRM/MRM approaches

  • Data-independent acquisition methods

  • Label-free quantification techniques

• Next-generation sequencing applications:

  • Spatial transcriptomics for localization studies

  • Single-cell protein analysis through oligonucleotide tagging

These emerging technologies address many limitations of antibody-based detection, though each comes with its own challenges and optimization requirements .

What are the implications of antibody reproducibility concerns for research using AC100 Antibody?

The broader antibody reproducibility crisis has significant implications:

• Research integrity considerations:

  • Studies using only manufacturer-validated antibodies like AC100 may be at risk for irreproducible results

  • A comprehensive study found that antibodies failing validation had been used in hundreds of publications

  • Researchers should implement validation practices beyond manufacturer specifications

• Publication requirements:

  • Journals increasingly require detailed antibody validation

  • Document catalog numbers, lot numbers, dilutions, and validation experiments

  • Consider publishing validation data as supplementary material

  • Follow antibody reporting guidelines (e.g., RRID identifiers)

• Reproducibility enhancement strategies:

  • Implement independent validation protocols before critical experiments

  • Consider moving to recombinant antibody alternatives with defined sequences

  • Participate in community validation efforts and share validation data

  • Use appropriate positive and negative controls in all experiments

These approaches align with recommendations from leading researchers addressing the "antibody validation crisis" in science .